Saikosaponin B2 Prevents Against BAP-induced Lungs Cancer in Mouse Model by Regulating Oxidative Stress

Abstract

Cancer of the lungs is the second most frequent form of cancer overall and has the greatest mortality rate because to its severe pathological abnormalities. In lung cancer, abnormal cell proliferation causes the alveolar duct to clot. Lung cancer is difficult to treat due to its clinical and biological heterogeneity, which necessitates the development of new therapeutic approaches or the refinement of existing ones. To investigate this, saikosaponin b2 was administered to mice with lung cancer caused by B(a)P. (SSb2). BAP is considered a group one carcinogen by the International Agency for Research on Cancer (IARC). Therefore, B(a)P may play a role in producing lung cancer. Albino balb/c mice were given B(a)P on alternate days over a 4-week period to induce cancer, with DMBA given weekly to encourage tumor growth. Beginning in the third week, SSb2 was given daily for twenty days. The drug's potential anti-cancer effects were studied by examining hepatic biomarkers, lung histology, and oxidative stress indicators. Increases in SOD, CAT, GST, and GSH levels accompanied by decreases in MDA levels and enhanced B(a)P detoxification after SSb2 treatment, which also improved liver function. Histopathology data showed that as compared with the B(a)P alone group, SSb2 reduced inflammation, membrane blebbing, and alveolar structure began returning to normal.